ARCHIVES

Addition of Immune Stimulant To Yervoy Therapy Increases Overall Survival, Study Says

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

FDA Says Medicare Policy On ESAs “Consistent With The Available Data.”

October 19, 2007

Simone Retires From Academic Medicine, But Plans To Remain Active In Advisory Roles.

September 7, 2001

Vasopermeation Technology Awarded Patent For CA Firm.

September 28, 2001

Translplants Not Best Choice in Subset of ALL Patients

April 27, 2012

Also in this 8-page issue: Amgen names PhRMA executive Rodger Currie vice president for government affairs.

April 30, 2004

Revlimid Also Demonstrates Response in Mantle Cell

July 29, 2011